2022 journal article

Effect of BIO-PLYTM, a Platelet-Rich Plasma Derived Biologic on PRRSV-2-Infected Macrophages


By: A. Frias-De-Diego  n, J. Gilbertie *, F. Scholle n, S. Dejarnette n & E. Crisci n 

co-author countries: United States of America πŸ‡ΊπŸ‡Έ
author keywords: antivirals; biologic; porcine macrophages; PRRSV
MeSH headings : Humans; Swine; Animals; Horses; Porcine respiratory and reproductive syndrome virus; Porcine Reproductive and Respiratory Syndrome / prevention & control; Macrophages; Biological Products
Source: ORCID
Added: November 29, 2022

Porcine Reproductive and Respiratory Syndrome (PRRS) is the one of the most devastating diseases impacting the swine industry worldwide. Control and prevention methods rely on biosafety measures and vaccination. As an RNA virus with a high rate of mutation, vaccines are only partially effective against circulating and newly emerging strains. To reduce the burden of this disease, research on alternative control methods is needed. Here, we assess the in vitro antiviral effect of a novel platelet-rich plasma-derived biologic termed BIO-PLYTM (for the BIOactive fraction of Platelet-rich plasma LYsate) from both swine and equine origin. Our results show that BIO-PLYTM significantly reduces the amount of PRRSV viral load determined by RT-qPCR and the number of infectious viral particles measured by TCID50 in infected porcine alveolar and parenchymal macrophages. This study also showed limited toxicity of BIO-PLYTM in vitro and aspects of its immunomodulatory capacity evaluating the regulation of reactive oxygen species and cytokines production in infected cells. Finally, this study presents promising data on the effect of BIO-PLYTM on other RNA viruses such as human A influenza viruses and coronavirus.